Innovative targets for circadian drug discovery: REV-ERBalpha and RORalpha

Every cell in the human body keeps time, and a pair of proteins called REV-ERBalpha and RORalpha act as molecular hands on that clock. This project will design and test chemical compounds that latch onto those proteins, giving researchers a way to deliberately reset or adjust the body’s internal timing. The problem is that while scientists know disrupted circadian rhythms are linked to chronic inflammation, diabetes, and heart disease, no drugs exist that directly target the clock’s molecular machinery. Current treatments treat symptoms, not the underlying timing fault. This work fills that gap by creating the first tool compounds that can toggle REV-ERBalpha and RORalpha on and off. If successful, these chemical probes will let researchers test whether correcting clock function can tamp down inflammation in living models. The ultimate goal is to deliver lead molecules ready for clinical development—potentially opening a new class of drugs that treat disease by fixing the body’s schedule rather than just its chemistry. This is fundamental science with a clear translational path: understanding how the clock ticks at a molecular level could eventually produce treatments for conditions as varied as arthritis, metabolic syndrome, and sleep disorders.